21st Annual Drug Discovery Summit: Virtual Event

Call for Papers

FREE ACCESS: Join us on the 29 - 30 July 2020 for the Drug Discovery Summit: Virtual Event 

This exciting new digital format enables a wider global audience of IO leaders to connect. The Virtual Event is the culmination of increased online resources Oxford Global is sharing in the coming months, providing access to key industry members and abundant educational and knowledge sharing resources, helping the sector grow and adapt during these uncertain times.

Register Now:  https://bit.ly/3eTP5DQ 

What's Included?

Fully Immersive Event Environment: Access presentations, networking areas and the exhibitor hall virtually.

Unique Attendee Profiles: Build your user profile and interact with 350+ leaders at the forefront of research into the immune system and other attendees via instant live chat.

Your profile also allows you to;

- Exchange Business Cards

- Build a 'buddy' list of contacts

- Integrate Linked In, Facebook and Twitter

- Make use of your own 'Event Bag' for downloading content

Same Quality Programme, Delivered in a New Format: The Event programme will be replicated through a mixture of on-demand and live-featured presentations in the Virtual Auditorium. Plus bonus 'virtual event' speakers, the event offers a wealth of viewing opportunity and educational content.

Engage through Virtual Networking, Meetings and Live Chat: See who is live at the event and interact in real time, or send direct messages to any registered attendee.

Visit Exhibitors Booths of Key Industry Providers: Exhibitor booths are fully featured spaces for product demo's, live interactions and 1-2-1 meeting scheduling.

Time: 08:30 to 17:00

Speakers: Steve Rees, Vice President Discovery Biology, AstraZeneca R and D Biopharmaceuticals Discovery Sciences , Ulrich A.K. Betz, Vice President Innovation, Department Head Future Insight, Merck KGaA , Thorsten Thormann, Vice President, Research, LEO Pharma ,  Alex Gouliaev, Vice President, Amgen ,  Michael R. Myers, Senior Director, LRL - Due Diligence, Eli Lilly and Company , Oliver Rausch, CSO, Storm Therapeutics